THU0127 IMMUNOGENICITY AND SAFETY OF 23-VALENT PNEUMOCOCCAL VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM 5-YEAR FOLLOW UP
Д. В. Буханова(Association of Rheumatologists of Russia), M. Cherkasova(Association of Rheumatologists of Russia), Yury Muravyev(Association of Rheumatologists of Russia), Б. С. Белов(Association of Rheumatologists of Russia), G. Lukina(Association of Rheumatologists of Russia), M. S. Sergeeva(Association of Rheumatologists of Russia), Galina Tarasova(Association of Rheumatologists of Russia), Н. В. Демидова(Association of Rheumatologists of Russia)
Cited by 9
Related Papers
Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia
|Rheumatology Science and Practice|2021|54
COVID-19: the new challenge for rheumatologists
|Modern Rheumatology Journal|2020|30
Comorbid infections in rheumatic diseases (according to FSBI RIR named after V.A. Nasonova)
|Meditsinskiy sovet = Medical Council|2019|14
Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review
|Rheumatology Science and Practice|2021|14
Vaccination against SARS-CoV-2 in rheumatic diseases: Safety issues
|Rheumatology Science and Practice|2022|13